Invasive aspergillosis (IA) has been reported to yield high mortality rates. Patients with an unfavourable prognostic haematological disease not only have a higher probability of developing IA but are also more likely to die due to causes directly related to the underlying disease. This complexity of risk mechanisms confounds the causal interpretation of IA occurrence and mortality. Full consideration of the changing patient characteristics over time is necessary to obtain reliable estimates of the correlation of IA with mortality. We studied the effect of IA on mortality in 167 consecutive patients starting with remission-induction therapy for AML or of whom most patients continued to haematopoietic stem cell transplantation (HSCT). No standard antifungal prophylaxis was administered in the period before HSCT. Survival analyses were performed to determine risk estimates of IA for different phases of treatment before and after HSCT. Time-dependent adjustment for confounding variables was performed using Cox proportional hazards models. In 55 of 167 enroled patients, IA was diagnosed. Before HSCT, adjusted hazard ratios and 95% confidence intervals on mortality after the diagnosis of IA were 3.5 (1.7-7.5), 2.0 (0.69-5.9), 2.3 (0.79-6.8) and 0.80 (0.49-1.4) within 30 days, between 30 and 60 days, between 60 and 90 days or more than 90 days, respectively. A similar pattern was observed after HSCT. The occurrence of IA did not significantly influence the decision to follow through with HSCT. The results provide new insights in short-and longterm survival of patients diagnosed with IA. A significantly increased mortality risk was only observed in the first month after diagnosis of IA. No unfavourable association with mortality was observed in the later course of treatment. The occurrence of IA did not affect the probability of attaining HSCT in our population.
INTRODUCTION
The prognosis of patients with haematological malignancies has improved over the past decades by the development of new anti-leukaemic agents, intensification of chemotherapeutic regimens and the use of haematopoietic stem cell transplantation (HSCT). 1, 2 However, these therapeutic advances have increased the risk of invasive fungal infections, especially in patients undergoing intensive chemotherapy or HSCT. 3, 4 Patients treated for AML or high-risk myelodysplastic syndrome (MDS) are particularly prone to the development of invasive aspergillosis (IA) due to the impact of both the intensive chemotherapy and the effect of the disease itself on granulocyte function, which is considered to be the most important host defence against invasive fungal disease. 5, 6 Despite currently available antifungal prophylaxis and treatment, development of IA still leads to high mortality rates. 3, 4 The most important risk factors for IA in patients with haematological malignancies have been described in several studies, comprising both different host factors (for example, prolonged periods of neutropenia) and different treatment characteristics. [7] [8] [9] In AML and MDS, many of the factors that convey a higher risk for IA also independently contribute to treatment failure, susceptibility to other complications and mortality due to a combination of high-risk treatment protocols and severity of the underlying disease. In addition, because pre-and post-transplantation states are very distinct in terms of host immunity, many risk factors associated with mortality have been found to differ before and after transplantation. [10] [11] [12] This complexity of risk mechanisms confounds the causal interpretation of the association between occurrence and mortality of IA. Because of these complex mechanisms, the correlation between the occurrence of IA and its effect on long-term survival (that is, longer than 6 weeks) in patients with AML or MDS remains to be clarified. In-depth analyses of patient characteristics, treatment phase and competing risks over time are needed to obtain reliable estimates of the short-and long-term impact of IA on mortality in this vulnerable patient population.
In this study, we aimed to present a new and comprehensive method to study the short-and long-time effect of IA on the survival of patients receiving treatment for AML or high-risk MDS.
PATIENTS AND METHODS

Setting and study population
The study was performed at the Leiden University Medical Center, a tertiary care and teaching hospital in the Netherlands, which is committed to solid organ and haematological transplantation programmes. All patients treated for AML or high-risk MDS between 1 January 2005 and 31 December 2011 with at least one course of remission-induction chemotherapy were included in our study. Follow-up started at diagnosis of AML or MDS and ended on 1 July 2012 or with the death of the patient. Almost all patients proceeded to HSCT after achieving complete remission with intensive chemotherapy. There were no considerable changes in treatment of AML or high-risk MDS, diagnostic strategies or antibacterial prophylaxis and empirical therapy strategies within the time period of the study. During the study, patients did not receive systemic mould-active antifungal prophylaxis. Periodic screening for invasive fungal infection by serum galactomannan or β-D-glucan assays was not performed. A standardised protocol for diagnosis of suspected fungal infection was in place. In case of suspected fungal infection, for example, in patients with persistent fever for at least 3 days without another evident cause, a high resolution CT-scan of the lungs was performed. If the scan showed intrapulmonary abnormalities, bronchoalveolar lavage (BAL) and/or lung biopsy was performed. BAL fluid samples were subjected to direct staining for fungi, fungal culture and galactomannan assay. In addition to the BAL, or in case a BAL was not possible, serum galactomannan tests were executed in neutropenic patients suspected for IA. A galactomannan of 40.5 in fluid obtained by BAL or 41.0 in serum was considered a positive test result. After review by the local ethics committee, a waiver of the need for informed consent was issued.
Collection of data and definitions
Patient data were extracted from the electronic patient file system. These included age, sex, pre-existing co-morbidities (lung disease, diabetes or previous malignancies) and characteristics of haematological disease. Collected characteristics were disease-specific genetic abnormalities, risk group of disease according to the World Health Organization classification system, use of G-CSF in any treatment phase, the chemotherapeutic regimen and the total number of induction therapies needed to achieve remission of the haematological disease. The database was anonymised on completion and the decryption key was stored on a secure hospital drive. A single patient could contribute two disease episodes to the cohort if a relapse occurred within the study period. A new episode was counted as soon as the diagnosis of relapsed disease was confirmed and started with a new pre-transplant period. Specific diagnostic tests concerning the diagnosis of IA as described in the 2008 revised European Organisation for Research and Treatment of Cancer criteria were collected (that is, computed tomography scan, BAL fluid analysis and serum galactomannan tests). Subsequently, each case was categorised accordingly as possible, probable, proven or indefinite IA. Patients meeting the revised 2008 European Organisation for Research and Treatment of Cancer criteria 13 of having possible, probable or proven IA were regarded to have IA. Patients who were treated for fungal disease other than IA or were empirically treated with antifungal agents but did not meet the criteria for at least a possible IA were censored from the moment antifungal therapy was initiated. As these patients are in a state in which the chance of occurrence of at least possible IA is significantly decreased, they could not be considered a representative control. The date of IA diagnosis was defined as the day of start of antifungal treatment. The laboratory results for every patient were examined for appraisal of neutropenic status. A neutropenic period was defined as the time between the first day of neutropenia (that is, a neutrophil count below 500 cells/μl) and the first day of resolution of neutropenia (neutrophil counts rising above this number).
Statistical analyses
The time periods before and after transplantation are two very distinct phases with regard to both treatment and immunological host factors. Consequently, many of the studied variables can act differently from one phase to the other. As reaching HSCT is an obligatory step in achieving definite remission and therefore is a critical factor in the survival of these patients, it was treated as an intermediate endpoint. We aimed to divide the follow-up data accordingly and therefore the analysis contains three separate pathways within the disease episode, which are visualised in a multi-state model: 14 first, a route to death in the pre-transplant period; second, a route to transplantation; and third, a route to death in the posttransplant period ( Figure 1 ). Correspondingly, a set of three survival analyses based on Cox regression models accounting for the different phases in treatment were constructed, considering (I) time from diagnosis to death before HSCT, (II) time from diagnosis to HSCT and (III) time from HSCT to death after HSCT. Most studied clinical variables have an immutable nature (for example, the patients gender); in contrast, Figure 1 . Phases of treatment of haematological malignancy corresponding to analytical models estimating the probability of death after diagnosis of IA. Arrows represent possible pathways during treatment for haematological malignancy. Numbered pathways correspond to the relevant models in Table 2 and Figure 3 . 
RESULTS
Study population
The cohort of patients receiving remission-induction therapy with the goal of attaining HSCT for AML or high-risk MDS consisted of 173 patients (Table 1) . Of these patients, 94 were male and the median age was 54 years. In the pre-transplant period, patients who received mould-active antifungal agents for reason other than treatment of at least possible IA were censored at the moment of start of therapy (n = 6). Reasons for the use of fungicidal drugs for purposes other than treatment of IA were the following: chemoprophylaxis for IA (n = 1), aborted empirical treatment (n = 4) and invasive fungal infection other than IA (n = 1). In 55 patients, IA was diagnosed and 112 patients (contributing 129 episodes) never experienced IA during followup. IA occurred in 45 patients before transplantation and in 10 patients after transplantation. None of the patients developed IA more often than once during the study period. The incidence of IA did not increase over the years during the study period (χ 2 -test P = 0.095). In 12 (22%) cases either sputum or BAL samples yielded a positive culture. Fungal cultures displayed the usual distribution of Aspergillus spp.: 11 A. fumigatus and 1 A. flavus were identified. One cultured A. fumigatus was found to be resistant for itraconazole, posaconazole and voriconazole. As some patients developed a relapse of the haematological malignancy within the period of study, all 173 patients contributed a total of 190 episodes of treatment to the study.
Survival data HSCT was performed after 100 (54%) of 184 episodes of remissioninduction chemotherapy. In a total of 71 episodes (39%), the patient died before HSCT. For the remaining 13 episodes (7%), patients were not transplanted and still alive at the end of the period of study (Figure 2) . Table 2 shows the increase in hazard after the diagnosis of IA, after adjusting for use of G-CSF, age, sex, World Health Organization haematological risk category, number of chemotherapy courses needed to accomplish complete remission, previous lung disease, secondary or relapsed haematological disease and the presence of neutropenia ( Table 2) . The different models correspond to the pathways visualised in Figure 1 : Model 1 describes the hazard of death before HSCT, model 2 the hazard of reaching the point of HSCT and model 3 the hazard of death after HSCT. The relative effects of individual factors remained constant in the different post-IA time periods and different treatment phases.
The hazard ratios for survival with 95% confidence intervals for different time periods after the diagnosis of IA as presented in Table 2 are shown graphically (Figure 3) per different treatment phase. Shortly after diagnosis of IA, the hazard of mortality both before and after HSCT is increased. This effect decreased over time and after 1 month in the pre-transplant phase, or after 2 months in the post-transplant phase, a significant effect is no longer observed. The probability to receive stem cell transplantation was not significantly altered by the occurrence of IA as shown in the second model (Figure 3 ). 
DISCUSSION
In this study, we applied a novel approach to study the association of IA and mortality over time. This association is complicated by several confounding factors and is not only challenging to appraise from an analytical perspective, but is also difficult to interpret for the clinician at the bedside of the individual patient. Mortality caused by IA is typically due to haemorrhage of lung lesions, insufficient oxygenation or dissemination to other vital organs such as the brain. 15, 16 In clinical practice however, only a relatively small number of patients with IA dies from an obvious IA-related cause. This proportion further decreases over time, from the day of diagnosis of IA. 3, 17, 18 Different studies that assessed IA mortality in the past concluded that the directly attributable mortality is relatively low when compared to all-cause mortality following infection. 2, [19] [20] [21] [22] Factors associated with the development of IA are also predictors for an unfavourable outcome, even so in the absence of IA. 7, 9, 23, 24 In some cases, the development of IA can be a phenomenon accompanying a deteriorating physical condition due to other fatal complications (for example, pseudomonas sepsis) or be part of a polymicrobial infection, as has been reported in different cohort studies. 25, 26 These previous findings, combined with the high baseline mortality of haematological patients, could easily give rise to overestimation of the IA-attributable mortality. As a result, the appraisal of prophylactic strategies is complicated.
We found that the association between IA and mortality remains strong even after accounting for risk factors attributable to the unfavourable underlying disease. Both before and after HSCT, the mortality hazard is substantially increased shortly after the diagnosis of IA. However, within a relatively short period of time the effect of IA on the risk of death decreased. The mortality rates may then be directed by other host factors. A decrease of transplantation probability was observed within the first month after diagnosis of IA, but the effect was not statistically significant. This suggests that occurrence of IA might deter the clinician to proceed with a planned HSCT in the initial phase. Delay of HSCT for any reason lowers the probability of complete remission of haematological malignancy and is therefore undesirable. 27, 28 The results stress the importance of effective management in the initial phase (that is, the first month) after diagnosis. In light of increasing resistance rates of Aspergillus spp. worldwide, 29 determination of azole susceptibility should be pursued quickly to ensure the use of adequate therapy as soon as possible. This especially holds true in areas with high resistance rates. The applicability of the results is restricted by the selection of a population that consists of patients that have a high risk of IA. Other populations at risk for IA, such as solid-organ transplant recipients, develop IA in the background of a very different risk profile and are not comparable to the population described in this study. The study is somewhat limited by the size of the cohort, but despite the retrospective acquisition of the data, all episodes were well documented in our hospital system. According to the methods described, we have included patients with possible IA, because the results would best reflect a 'real life clinical setting'. Although the a priori chance of the presence of IA is theoretically smaller in the group of possible aspergillosis, the clinical consequences do not largely differ in terms of treatment and follow-up measures. As Herbrecht et al. 30 explain in their study implementing the updated 2008 European Organisation for Research and Treatment of Cancer definitions for IA, the diagnosis of possible aspergillosis in the clinical setting very likely corresponds to the presence of disease, albeit usually in an earlier stadium with a more favourable prognosis. The inclusion of possible aspergillosis in this study contributes to the overall applicability of the results to the clinical situation. For an attending physician, a patient has the diagnosis IA, and is treated for it, or does not have the diagnosis and is not treated for it.
A major strength of this study is the availability of day-by-day data over the entire course of the haematological disease and its integration in a time-dependent model. The presence of factors strongly associated with both mortality and the occurrence of IA demands a detailed parsing of all possible confounding factors for an accurate measurement of effect. Second, the study has a large number of participants without primary prophylaxis in the pre-transplantation period; this provides a mortality risk that does not rely on break-through infection or prophylaxis intolerance. Future research would benefit from a protocolised method to establish the presence of co-infection and the cause of death. This would allow more precise calculation of attributable mortality rates of IA. Though difficult to achieve, high autopsy rates The impact of invasive aspergillosis on mortalityproviding a more verifiable way to establish the cause of death, would also be a valuable addition to future studies.
In conclusion, a detailed survival model of patients with AML or high-risk MDS was established separately for all different treatment phases, focussing on the impact of IA on mortality in this population. The results show that the effect of IA on mortality is initially substantial. However, although an increased risk of death was significantly present in the first and second month after diagnosis of IA, no unfavourable association with mortality was observed in the later course of treatment. Thus, IA should not be considered as an independent determinant in long-term survival of patients treated for AML or high-risk MDS.
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